Senores Pharmaceuticals Ltd (SENORES) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 10039497, "name": "Senores Pharma.", "stock_name": "Senores Pharma.", "full_name": "Senores Pharmaceuticals Ltd", "name_url": "stocks-analysis/senores-pharma", "exchange": 0, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "1,361.25", "chg": 6.7, "chgp": "0.49%", "dir": 1, "prev_price": "1,354.55", "mcapval": "6,211.00 Cr", "mcap": "Small Cap", "scripcode": 544319, "symbol": "SENORES", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "sector_id": 65, "indexname": "India SENSEX", "isin": "INE0RB801010", "curr_date": "Aug 04, 03:30 PM", "curr_time": "07:08 AM", "last_traded_at": "Aug 04, 03:30 PM IST", "bse_nse_vol": "1.09 lacs", "exc_status": "Active", "traded_date": "Aug 04, 2026", "traded_date_str": "2026 08 04", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/senores-pharma-10039497-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Senores Pharmaceuticals Falls 6.11%: 4 Key Factors Driving the Weekly Decline", "link": "https://www.marketsmojo.com/news/stocks-in-action/senores-pharmaceuticals-falls-611-4-key-factors-driving-the-weekly-decline-4130999", "imagepath": "", "date": "2026-08-01 10:00:07", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>27 Jul:</strong> Q1 FY27 results show robust growth momentum despite margin pressure</p>\n <p><strong>28 Jul:</strong> Stock hits intraday low amid significant price pressure</p>\n <p><strong>29 Jul:</strong> Downgrade to Hold by MarketsMOJO amid mixed technical and valuation concerns</p>\n <p><strong>31 Jul:</strong> Week closes at Rs.1,301.50, down 6.11% for the week</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,386.15</div></div>\n <div class=\"stat-item\"><div class=\"stat-label..." }, { "title": "Senores Pharmaceuticals Downgraded to Hold Amid Mixed Technical Signals and Valuation Concerns", "link": "https://www.marketsmojo.com/news/stock-recommendation/senores-pharmaceuticals-downgraded-to-hold-amid-mixed-technical-signals-and-valuation-concerns-4125376", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/SenoresPharmace_mojoScore_4125376.png", "date": "2026-07-29 08:39:14", "description": "Senores Pharmaceuticals Ltd has seen its investment rating downgraded from Buy to Hold as of 28 July 2026, reflecting a nuanced reassessment across quality, valuation, financial trends, and technical indicators. Despite robust financial performance and market-beating returns, evolving technical signals and valuation metrics have tempered enthusiasm, prompting a more cautious stance from analysts." }, { "title": "Senores Pharmaceuticals Ltd Sees Technical Momentum Shift Amid Mixed Indicator Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/senores-pharmaceuticals-ltd-sees-technical-momentum-shift-amid-mixed-indicator-signals-4125226", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/SenoresPharmace_technicaldot_4125226.png", "date": "2026-07-29 08:04:39", "description": "Senores Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, reflected in a recent downgrade from a Buy to a Hold rating. Despite a strong year-to-date return of 61.4%, the stock’s price has softened sharply in the past week, prompting a reassessment of its near-term outlook amid mixed technical indicator signals." }, { "title": "Are Senores Pharmaceuticals Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-senores-pharmaceuticals-ltd-latest-results-good-or-bad-4124655", "imagepath": "", "date": "2026-07-28 19:18:39", "description": "Senores Pharmaceuticals Ltd's latest financial results for Q1 FY27 reflect a complex operational landscape. The company reported net sales of ₹180.21 crores, marking a year-on-year growth of 30.60% and a sequential increase of 2.87% from the previous quarter. This consistent revenue growth over the past seven quarters indicates strong demand for its products and effective market penetration strategies.\n\nHowever, the consolidated net profit for the quarter was ₹30.72 crores, which represents a sequential decline of 2.82% compared to the previous quarter, despite a significant year-on-year increase of 55.70%. This decline in net profit is attributed to elevated interest costs and a normalization of other income, which had previously been unusually high.\n\nThe operating margin, excluding other income, improved to 29.83%, reflecting an increase of 269 basis points from the previous quarter, suggesting enhanced o..." }, { "title": "Senores Pharmaceuticals Ltd Hits Intraday Low Amid Price Pressure", "link": "https://www.marketsmojo.com/news/stocks-in-action/senores-pharmaceuticals-ltd-hits-intraday-low-amid-price-pressure-4123789", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/SenoresPharmace_priceRelatedfactors_4123789.png", "date": "2026-07-28 09:32:36", "description": "Senores Pharmaceuticals Ltd experienced a significant intraday decline on 28 Jul 2026, with the stock touching a low of Rs 1,298.8, marking a 7.98% drop from previous levels. This underperformance comes amid heightened volatility and price pressures that contrasted with the broader market’s modest gains." }, { "title": "Senores Pharmaceuticals Q1 FY27: Robust Growth Momentum Continues Despite Margin Pressure", "link": "https://www.marketsmojo.com/news/result-analysis/senores-pharmaceuticals-q1-fy27-robust-growth-momentum-continues-despite-margin-pressure-4123011", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/SenoresPharmace_quaterlyResult_4123011.png", "date": "2026-07-27 20:47:31", "description": "Senores Pharmaceuticals Ltd., a small-cap pharmaceutical company with a market capitalisation of ₹6,444.00 crores, reported consolidated net profit of ₹30.72 crores in Q1 FY27, reflecting a modest sequential decline of 2.82% from Q4 FY26 but a robust year-on-year surge of 55.70%. The stock responded positively to the results, gaining 1.83% to close at ₹1,411.50 on July 27, 2026, as investors focused on the company's sustained revenue growth trajectory and strong demand fundamentals." }, { "title": "When is the next results date for Senores Pharmaceuticals Ltd?", "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-senores-pharmaceuticals-ltd-4116758", "imagepath": "", "date": "2026-07-22 23:17:45", "description": "The next results date for Senores Pharmaceuticals Ltd is scheduled for July 27, 2026...." }, { "title": "Senores Pharmaceuticals Ltd is Rated Buy", "link": "https://www.marketsmojo.com/news/stock-recommendation/senores-pharmaceuticals-ltd-is-rated-buy-4109007", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/SenoresPharmace_mojoScore_4109007.png", "date": "2026-07-20 10:10:41", "description": "Senores Pharmaceuticals Ltd is rated Buy by MarketsMOJO, with this rating last updated on 08 July 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 20 July 2026, providing investors with the most up-to-date view of the stock’s fundamentals, returns, and technical outlook." }, { "title": "Senores Pharmaceuticals Ltd Falls 1.16%: 2 Key Factors Driving the Week", "link": "https://www.marketsmojo.com/news/stocks-in-action/senores-pharmaceuticals-ltd-falls-116-2-key-factors-driving-the-week-4106871", "imagepath": "", "date": "2026-07-18 10:00:10", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>13 Jul:</strong> Stock opens at Rs.1,433.85, gaining 1.26%</p>\n <p><strong>14 Jul:</strong> Continued gains, closing at Rs.1,450.40 (+1.15%)</p>\n <p><strong>15 Jul:</strong> Strong rally to Rs.1,478.85 (+1.96%)</p>\n <p><strong>16 Jul:</strong> Senores Pharmaceuticals Ltd hits new 52-week and all-time high at Rs.1,487.30</p>\n <p><strong>17 Jul:</strong> Sharp decline to Rs.1,399.55 (-3.68%) on heavy volume</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,433.85</div></div>\n ..." } ], "total": 283, "sid": "10039497", "stock_news_url": "https://www.marketsmojo.com/news/senores-pharmaceuticals-10039497" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript", "datetime": "03-Aug-2026", "details": "Senores Pharmaceuticals Limited has informed the Exchange regarding Transcript of Earnings Conference Call held on Monday July 27 2026 for Q1FY27.", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "28-Jul-2026", "details": "Senores Pharmaceuticals Limited has informed the Exchange regarding Newspaper Publication Extracts of Unaudited Financial Results of the Company for quarter ended June 30 2026", "source": "BSE" }, { "caption": "Board Meeting Outcome for Outcome Of Board Meeting", "datetime": "27-Jul-2026", "details": "Senores Pharmaceuticals Limited has informed exchange regarding Outcome of Board Meeting held on July 27 2026", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "No <strong>Dividend</strong> history available", "data": [] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

27 Jul: Q1 FY27 results show robust growth momentum despite margin pressure

28 Jul: Stock hits intraday low amid significant price pressure

29 Jul: Downgrade to Hold by MarketsMOJO amid mixed technical and valuation concerns

31 Jul: Week closes at Rs.1,301.50, down 6.11% for the week

Week Open

Rs.1,386.15

Read full news article

Senores Pharmaceuticals Downgraded to Hold Amid Mixed Technical Signals and Valuation Concerns

2026-07-29 08:39:14

Senores Pharmaceuticals Ltd has seen its investment rating downgraded from Buy to Hold as of 28 July 2026, reflecting a nuanced reassessment across quality, valuation, financial trends, and technical indicators. Despite robust financial performance and market-beating returns, evolving technical signals and valuation metrics have tempered enthusiasm, prompting a more cautious stance from analysts.

Read full news article

Senores Pharmaceuticals Ltd Sees Technical Momentum Shift Amid Mixed Indicator Signals

2026-07-29 08:04:39

Senores Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, reflected in a recent downgrade from a Buy to a Hold rating. Despite a strong year-to-date return of 61.4%, the stock’s price has softened sharply in the past week, prompting a reassessment of its near-term outlook amid mixed technical indicator signals.

Read full news article

Are Senores Pharmaceuticals Ltd latest results good or bad?

2026-07-28 19:18:39

Senores Pharmaceuticals Ltd's latest financial results for Q1 FY27 reflect a complex operational landscape. The company reported net sales of ₹180.21 crores, marking a year-on-year growth of 30.60% and a sequential increase of 2.87% from the previous quarter. This consistent revenue growth over the past seven quarters indicates strong demand for its products and effective market penetration strategies. However, the consolidated net profit for the quarter was ₹30.72 crores, which represents a sequential decline of 2.82% compared to the previous quarter, despite a significant year-on-year increase of 55.70%. This decline in net profit is attributed to elevated interest costs and a normalization of other income, which had previously been unusually high. The operating margin, excluding other income, improved to 29.83%, reflecting an increase of 269 basis points from the previous quarter, suggesting enhanced o...

Read full news article

Senores Pharmaceuticals Ltd Hits Intraday Low Amid Price Pressure

2026-07-28 09:32:36

Senores Pharmaceuticals Ltd experienced a significant intraday decline on 28 Jul 2026, with the stock touching a low of Rs 1,298.8, marking a 7.98% drop from previous levels. This underperformance comes amid heightened volatility and price pressures that contrasted with the broader market’s modest gains.

Read full news article

Senores Pharmaceuticals Q1 FY27: Robust Growth Momentum Continues Despite Margin Pressure

2026-07-27 20:47:31

Senores Pharmaceuticals Ltd., a small-cap pharmaceutical company with a market capitalisation of ₹6,444.00 crores, reported consolidated net profit of ₹30.72 crores in Q1 FY27, reflecting a modest sequential decline of 2.82% from Q4 FY26 but a robust year-on-year surge of 55.70%. The stock responded positively to the results, gaining 1.83% to close at ₹1,411.50 on July 27, 2026, as investors focused on the company's sustained revenue growth trajectory and strong demand fundamentals.

Read full news article

When is the next results date for Senores Pharmaceuticals Ltd?

2026-07-22 23:17:45

The next results date for Senores Pharmaceuticals Ltd is scheduled for July 27, 2026....

Read full news article

Senores Pharmaceuticals Ltd is Rated Buy

2026-07-20 10:10:41

Senores Pharmaceuticals Ltd is rated Buy by MarketsMOJO, with this rating last updated on 08 July 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 20 July 2026, providing investors with the most up-to-date view of the stock’s fundamentals, returns, and technical outlook.